Conventional fractionation should not be the standard of care for T2 glottic cancer.
dc.contributor.author | Dixon, Lynne | |
dc.contributor.author | Douglas, C | |
dc.contributor.author | Shaukat, Shazril Imran | |
dc.contributor.author | Garcez, Kate | |
dc.contributor.author | Lee, Lip W | |
dc.contributor.author | Sykes, Andrew J | |
dc.contributor.author | Thomson, David J | |
dc.contributor.author | Slevin, Nicholas J | |
dc.date.accessioned | 2017-12-15T15:27:10Z | |
dc.date.available | 2017-12-15T15:27:10Z | |
dc.date.issued | 2017-11-14 | |
dc.identifier.citation | Conventional fractionation should not be the standard of care for T2 glottic cancer. 2017, 12 (1):178 Radiat Oncol | en |
dc.identifier.issn | 1748-717X | |
dc.identifier.pmid | 29137654 | |
dc.identifier.doi | 10.1186/s13014-017-0915-8 | |
dc.identifier.uri | http://hdl.handle.net/10541/620728 | |
dc.description.abstract | The aim of this study was to report outcomes and late toxicity following hypofractionated accelerated radiotherapy for T2 glottic cancers. We highlight the importance of hypofractionated treatments with shorter overall treatment times, in improving outcomes for T2 glottic cancers. We also compare the biologically effective dose of hypofractionated regimes, with conventional fractionation. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Radiation oncology (London, England) | en |
dc.title | Conventional fractionation should not be the standard of care for T2 glottic cancer. | en |
dc.type | Article | en |
dc.contributor.department | Department of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester | en |
dc.identifier.journal | Radiation Oncology | en |
refterms.dateFOA | 2018-12-17T15:10:38Z | |
html.description.abstract | The aim of this study was to report outcomes and late toxicity following hypofractionated accelerated radiotherapy for T2 glottic cancers. We highlight the importance of hypofractionated treatments with shorter overall treatment times, in improving outcomes for T2 glottic cancers. We also compare the biologically effective dose of hypofractionated regimes, with conventional fractionation. |